• Je něco špatně v tomto záznamu ?

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial

F. Saad, AJ. Armstrong, M. Oya, K. Vianna, M. Özgüroğlu, C. Gedye, GL. Buchschacher, JY. Lee, U. Emmenegger, J. Navratil, JA. Virizuela, A. Salazar, D. Maillet, H. Uemura, J. Kim, E. Oscroft, L. Barker, A. Degboe, NW. Clarke

. 2024 ; 7 (6) : 1394-1402. [pub] 20240406

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze III, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003344

BACKGROUND: The PROpel study (NCT03732820) demonstrated a statistically significant progression-free survival benefit with olaparib plus abiraterone versus placebo plus abiraterone in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting, irrespective of homologous recombination repair mutation status. OBJECTIVE: We report additional safety analyses from PROpel to increase clinical understanding of the adverse-event (AE) profiles of olaparib plus abiraterone versus placebo plus abiraterone. DESIGN, SETTING, AND PARTICIPANTS: A randomised (1:1), double-blind, placebo-controlled trial was conducted at 126 centres in 17 countries (October 2018-January 2020). Patients had mCRPC and no prior systemic mCRPC treatment. INTERVENTION: Olaparib (300 mg bid) or placebo with abiraterone (1000 mg od) plus prednisone/prednisolone (5 mg bid). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The data cut-off date was July 30, 2021. Safety was assessed by AE reporting (Common Terminology Criteria for Adverse Events v4.03) and analysed descriptively. RESULTS AND LIMITATIONS: The most common AEs (all grades) for olaparib plus abiraterone versus placebo plus abiraterone were anaemia (46.0% vs 16.4%), nausea (28.1% vs 12.6%), and fatigue (27.9% vs 18.9%). Grade ≥3 anaemia occurred in 15.1% versus 3.3% of patients in the olaparib plus abiraterone versus placebo plus abiraterone arm. The incidences of the most common AEs for olaparib plus abiraterone peaked early, within 2 mo, and were managed typically by dose modifications or standard medical practice. Overall, 13.8% versus 7.8% of patients discontinued treatment with olaparib plus abiraterone versus placebo plus abiraterone because of an AE; 3.8% versus 0.8% of patients discontinued because of anaemia. More venous thromboembolism events were observed in the olaparib plus abiraterone arm (any grade, 7.3%; grade ≥3, 6.8%) than in the placebo plus abiraterone arm (any grade, 3.3%; grade ≥3, 2.0%), most commonly pulmonary embolism (6.5% vs 1.8% for olaparib plus abiraterone vs placebo plus abiraterone). CONCLUSIONS: Olaparib plus abiraterone has a manageable and predictable safety profile. PATIENT SUMMARY: The PROpel trial showed that in patients who had not received any previous treatment for metastatic castration-resistant prostate cancer, olaparib combined with abiraterone was more effective in delaying progression of the disease than abiraterone alone. Most side effects caused by combining olaparib with abiraterone could be managed with supportive care methods, by pausing olaparib administration for a short period of time and/or by reducing the dose of olaparib.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003344
003      
CZ-PrNML
005      
20250206104258.0
007      
ta
008      
250121s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euo.2024.03.006 $2 doi
035    __
$a (PubMed)38582650
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Saad, Fred $u Centre Hospitalier de l'Université de Montréal/CRCHUM, Université de Montréal, Montreal, QC, Canada. Electronic address: fred.saad@umontreal.ca
245    10
$a Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial / $c F. Saad, AJ. Armstrong, M. Oya, K. Vianna, M. Özgüroğlu, C. Gedye, GL. Buchschacher, JY. Lee, U. Emmenegger, J. Navratil, JA. Virizuela, A. Salazar, D. Maillet, H. Uemura, J. Kim, E. Oscroft, L. Barker, A. Degboe, NW. Clarke
520    9_
$a BACKGROUND: The PROpel study (NCT03732820) demonstrated a statistically significant progression-free survival benefit with olaparib plus abiraterone versus placebo plus abiraterone in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting, irrespective of homologous recombination repair mutation status. OBJECTIVE: We report additional safety analyses from PROpel to increase clinical understanding of the adverse-event (AE) profiles of olaparib plus abiraterone versus placebo plus abiraterone. DESIGN, SETTING, AND PARTICIPANTS: A randomised (1:1), double-blind, placebo-controlled trial was conducted at 126 centres in 17 countries (October 2018-January 2020). Patients had mCRPC and no prior systemic mCRPC treatment. INTERVENTION: Olaparib (300 mg bid) or placebo with abiraterone (1000 mg od) plus prednisone/prednisolone (5 mg bid). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The data cut-off date was July 30, 2021. Safety was assessed by AE reporting (Common Terminology Criteria for Adverse Events v4.03) and analysed descriptively. RESULTS AND LIMITATIONS: The most common AEs (all grades) for olaparib plus abiraterone versus placebo plus abiraterone were anaemia (46.0% vs 16.4%), nausea (28.1% vs 12.6%), and fatigue (27.9% vs 18.9%). Grade ≥3 anaemia occurred in 15.1% versus 3.3% of patients in the olaparib plus abiraterone versus placebo plus abiraterone arm. The incidences of the most common AEs for olaparib plus abiraterone peaked early, within 2 mo, and were managed typically by dose modifications or standard medical practice. Overall, 13.8% versus 7.8% of patients discontinued treatment with olaparib plus abiraterone versus placebo plus abiraterone because of an AE; 3.8% versus 0.8% of patients discontinued because of anaemia. More venous thromboembolism events were observed in the olaparib plus abiraterone arm (any grade, 7.3%; grade ≥3, 6.8%) than in the placebo plus abiraterone arm (any grade, 3.3%; grade ≥3, 2.0%), most commonly pulmonary embolism (6.5% vs 1.8% for olaparib plus abiraterone vs placebo plus abiraterone). CONCLUSIONS: Olaparib plus abiraterone has a manageable and predictable safety profile. PATIENT SUMMARY: The PROpel trial showed that in patients who had not received any previous treatment for metastatic castration-resistant prostate cancer, olaparib combined with abiraterone was more effective in delaying progression of the disease than abiraterone alone. Most side effects caused by combining olaparib with abiraterone could be managed with supportive care methods, by pausing olaparib administration for a short period of time and/or by reducing the dose of olaparib.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x patologie $7 D064129
650    12
$a ftalaziny $x terapeutické užití $x škodlivé účinky $7 D010793
650    12
$a piperaziny $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D010879
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a senioři $7 D000368
650    12
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a androsteny $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D000736
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Armstrong, Andrew J $u Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA
700    1_
$a Oya, Mototsugu $u Keio University School of Medicine, Tokyo, Japan
700    1_
$a Vianna, Karina $u Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil
700    1_
$a Özgüroğlu, Mustafa $u Istanbul University Cerrahpaşa, Faculty of Medicine, Istanbul, Türkiye
700    1_
$a Gedye, Craig $u Calvary Mater Newcastle, Waratah, NSW, Australia
700    1_
$a Buchschacher, Gary L $u Kaiser Permanente Southern California, Los Angeles, CA, USA
700    1_
$a Lee, Ji Youl $u The Catholic University of Korea Seoul St Mary's Hospital, Seoul, South Korea
700    1_
$a Emmenegger, Urban $u Sunnybrook Research Institute, Toronto, ON, Canada
700    1_
$a Navratil, Jiri $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Virizuela, Juan Antonio $u Hospital Universitario Virgen Macarena, Sevilla, Spain
700    1_
$a Salazar, Anibal $u Instituto de Especialidades Urologicas, Santiago, Chile
700    1_
$a Maillet, Denis $u Centre Hospitalier Lyon Sud, Pierre-Bénite, France; Faculté de Médecine Jacques Lisfranc, Saint-Etienne, France
700    1_
$a Uemura, Hiroji $u Yokohama City University Medical Center, Kanagawa, Japan
700    1_
$a Kim, Jeri $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Oscroft, Emma $u AstraZeneca, Cambridge, UK
700    1_
$a Barker, Laura $u AstraZeneca, Cambridge, UK
700    1_
$a Degboe, Arnold $u AstraZeneca, Baltimore, MD, USA
700    1_
$a Clarke, Noel W $u The Christie and Salford Royal Hospital NHS Foundation Trusts, and University of Manchester, Manchester, UK
773    0_
$w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 7, č. 6 (2024), s. 1394-1402
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38582650 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104254 $b ABA008
999    __
$a ok $b bmc $g 2263237 $s 1239351
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 7 $c 6 $d 1394-1402 $e 20240406 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace